EBMT 2020 | Future of anti-BCMA CAR T-cell therapy in myeloma

Noopur Raje, MD, Massachussetts General Hospital, Boston, MA, discusses areas of improvement in anti-BCMA CAR T-cell therapy in multiple myeloma, including evaluating the durability of response to CAR T-cell therapy, as well as the use of off-the-shelf allogeneic CAR-T. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).